, Volume 59, Issue 4, pp 815–827


Adis New Drug Profile

DOI: 10.2165/00003495-200059040-00007

Cite this article as:
Clemett, D. & Markham, A. Drugs (2000) 59: 815. doi:10.2165/00003495-200059040-00007


  • ▴ Linezolid is an oxazolidinone antibacterial agent that acts by inhibiting the initiation of bacterial protein synthesis. Cross-resistance between linezolid and other inhibitors of protein synthesis has not been demonstrated.

  • ▴ Linezolid has a wide spectrum of activity against Gram-positive organisms including methicillin-resistant staphylococci, penicillin-resistant pneumococci and vancomycin-resistant Enterococcus faecalis and E. faecium. Anerobes such as Clostridium spp., Peptostreptococcus spp. and Prevotella spp. are also susceptible to linezolid.

  • ▴ Linezolid is bacteriostatic against most susceptible organisms but displays bactericidal activity against some strains of pneumococci, Bacteroides fragilis and C. perfringens.

  • ▴ In clinical trials involving hospitalised patients with skin/soft tissue infections (predominantly S. aureus), intravenous/oral linezolid (up to 1250mg mg/day) produced clinical success in >83% of individuals. In patients with community-acquired pneumonia, success rates were >94%.

  • ▴ Preliminary clinical data also indicate that twice daily intravenous/oral linezolid 600mg is as effective as intravenous vancomycin 1g in the treatment of patients with hospital-acquired pneumonia and in those with infections caused by methicillin-resistant staphylococci. Moreover, linezolid 600mg twice daily produced >85% clinical/microbiological cure in vancomycin-resistant enterococcal infections.

  • ▴ Linezolid is generally well tolerated and gastrointestinal disturbances are the most commonly occurring adverse events. No clinical evidence of adverse reactions as a result of monoamine oxidase inhibition has been reported.

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand